October 18, 2021
RTS,S/AS01 (Trade name: Moscow Rix; Mosquirix) is a recombinant protein malaria vaccine. In October 2021, the vaccine was approved by the World Health Organization for use in children. It is the first malaria vaccine to be introduced. The RTS,S vaccine has been produced since the late 1980s by scientists at SmithKline Beecham Biologicals (now GluxoSmithKline Vaccines) in Belgium. It was then further developed by GSK in collaboration with the Walter Reed Army Research Institute. under partial funding from the path malaria vaccine program and the Bill and Melinda Gates Foundation. The efficacy of the vaccine is 26 to 50% in infants and young children. In July 2015, the European Medicines Agency (EMA) approved the use of the vaccine. This vaccine is the first malaria vaccine approved for use. It is also the first human parasitic vaccine approved for use. On October 23, 2015, the World Health Organization (WHO) The Office of Strategic Immunization Advisory Experts (SAGE) and the Malaria Policy Advisory Committee (MPAC) jointly proposed pilot implementation in Africa. The pilot program started on April 23, 2019. in Malawi, 30 April 2019 in Ghana and 13 September 2019 in Kenya.